ĚěĂŔ´«Ă˝

The selected channel has been deleted from your list of favorites.

Our News on Newswise

Newswise: 6793b688a41d4_147793KopetzS.jpg

Combination of Dual-Targeted Therapies and Chemotherapy Shows High Response Rates in BRAF-Mutated Metastatic Colorectal Cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the...
24-Jan-2025 3:00 PM EST Add to Favorites

Newswise: 6790f85a6725a_20250122RHcancercells.jpg

MD Anderson Research Highlights for January 22, 2025

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s...
22-Jan-2025 12:00 PM EST Add to Favorites

Newswise: 678485cebbce7_Bewellbaytownforbeaumontreleasephoto.jpg

ExxonMobil donates $10 million to fund MD Anderson-led Be Well™ Beaumont initiative

In an effort to improve public health and reduce cancer risk in East Texas, leaders in Beaumont are working with The University of Texas MD Anderson Cancer Center to launch Be Well™ Beaumont through a newly announced $10 million gift from...
13-Jan-2025 6:35 PM EST Add to Favorites

Newswise: 678165d898779_paulcinciripini.jpg.resize.jpg

Chances of Quitting Smoking Improve with Integrated Care, Including Medication and Counseling

Smokers undergoing lung cancer screening may have the best chance of quitting if they receive integrated care, which includes medication and comprehensive counseling with tobacco treatment specialists, according to researchers at The University of...
10-Jan-2025 7:55 PM EST Add to Favorites

MD Anderson Research Highlights for January 9, 2025

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s...
9-Jan-2025 7:40 PM EST Add to Favorites

MD Anderson and Myriad Genetics Form Strategic Alliance to Evaluate Clinical Utility of Myriad’s Molecular Residual Disease Assay

MD Anderson and Myriad announced a five-year strategic collaboration to accelerate the clinical evaluation and development of Myriad's molecular residual disease assay.
7-Jan-2025 8:00 AM EST Add to Favorites

Newswise: 677417438442c_kevinnead.jpg.resize.810.1150.high.jpg

Patients with Heart Disease May Be at Increased Risk for Advanced Breast Cancer

Patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease (CVD) compared to those with early-stage cancer at diagnosis, according to researchers from The...
2-Jan-2025 8:00 AM EST Add to Favorites

MD Anderson Research Highlights for December 18, 2024

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s...
18-Dec-2024 10:15 PM EST Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world, and, in 1971, it became one of the nation’s first National Cancer Institute (NCI)-designated comprehensive cancer centers. MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Experts

Twitter

Facebook

close
1.34648